5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges

      , , , ,
      Reviews on Recent Clinical Trials
      Bentham Science Publishers Ltd.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.

          Related collections

          Author and article information

          Journal
          Reviews on Recent Clinical Trials
          RRCT
          Bentham Science Publishers Ltd.
          15748871
          January 01 2009
          January 01 2009
          : 4
          : 1
          : 34-41
          Article
          10.2174/157488709787047530
          19149761
          51bc1a8d-c640-464a-a943-cc79f70f90ba
          © 2009
          History

          Comments

          Comment on this article